Effect of VULM 1457, an ACAT inhibitor, on serum lipid levels and on real time red blood cell flow in diabetic and non-diabetic hamsters fed high cholesterol-lipid diet.
Acyl-coenzyme A: cholesterol O-acyltransferase (ACAT) catalyzes the formation of cholesterol/fatty acyl-coenzyme A esters. Accumulation of cholesterol esters leads to pathological changes connected with atherosclerosis. We have evaluated effects of a newly synthesized ACAT inhibitor, 1-(2,6-diisopropyl-phenyl)-3-[4-(4'-nitrophenylthio)phenyl] urea (VULM 1457), on serum lipid (cholesterol and triglycerides) levels and velocity of red blood cells (RBC) in non-diabetic and diabetic hamsters fed on high cholesterol-lipid (HCHL) diet during 3 months. The VULM 1457 effects on the paw microcirculation were assessed using capillary microscopy by measuring (RBC) velocity in vivo. Hamsters fed on HCHL diet became hypercholesterolemic with a dramatic increase in serum lipids accompanied with significantly decreased RBC velocity. Diabetic hamsters fed on HCHL diet had further increased serum lipids with reduction of RBC velocity. The VULM 1457 inhibitor lowered cholesterol levels in both non-diabetic and diabetic hamsters fed on HCHL diet. The greater VULM 1457 effect was shown in diabetic hamsters fed on HCHL diet where VULM 1457 expressed hypotriglycerides effects, too. An improved RBC velocity-pronounced effect was observed in diabetic hamsters fed on HCHL diet treated with VULM 1457. These results suggest that the ACAT inhibitor, VULM 1457, is a prospective hypolipidemic and anti-atherogenic drug which treats diabetes.
Vojtassáková
E
E
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Kalinciakova 8, 832 32 Bratislava, Slovakia. elenavojtassak@yahoo.com
Syneková
M
M
Tazká
D
D
Mátyás
S
S
Hózová
R
R
Sadlonová
I
I
Svec
P
P
D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000032:analysis / Q000097:blood* / Q000378:metabolism; D002791:Cholesterol, Dietary / Q000494:pharmacology; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000494:pharmacology; D006224:Cricetinae; D003920:Diabetes Mellitus / Q000378:metabolism* / Q000503:physiopathology; D004032:Diet; D004041:Dietary Fats / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects* / Q000502:physiology; D008055:Lipids / Q000097:blood*; D008297:Male; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014280:Triglycerides / Q000032:analysis / Q000097:blood
D001786:Blood Glucose; D002791:Cholesterol, Dietary; D004041:Dietary Fats; D008055:Lipids; D014280:Triglycerides; C505646:VULM 1457; D002784:Cholesterol; D002785:Sterol O-Acyltransferase; D002994:Clofibrate